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Özet
Amaç: İdiyopatik non-obstrüktif azospermili (NOA) hastalarda, ampirik hCG 
tedavisi ile ilgili sonuçları araştırmak. Gereç ve Yöntem: hCG grubunu normal 
testis hacimlerine ve normal serum FSH ve LH düzeylerine sahip olan ve am-
pirik hCG ile tedavi edilen 34 hasta oluşturdu. hCG, testiküler sperm ekstrak-
siyonundan (TESE) 10-14 hafta önce 2500 IU olarak haftada iki kere deri al-
tına enjeksiyon şeklinde uygulandı. Kontrol grubunu yaş ve eş yaşları hCG gru-
bu ile denk olup aynı dönemde TESE uygulanan 49 hasta oluşturdu. Gruplar 
arasındaki sperm elde etme oranı (SRR), folikül uyarıcı hormon (FSH), luteini-
zan hormon (LH), testosteron seviyeleri, testis hacimleri, fertilizasyon oranla-
rı (FR), implantasyon oranları (IR), gebelik oranları (PR), canlı doğum oranla-
rı (LBR), iptal oranları (CR) ve cerrahi tekniği arasındaki ilişki değerlendirildi.
Bulgular: Konvansiyonel teknik ile başarılı sperm elde edilmesi, hCG grubun-
daki 17 hasta’nın 14’ünde (% 82,3) olurken kontrol grubundaki 28 hasta’nın 
18’inde (% 64,3) sağlandı (p = 0,170). SRR açısından gruplar arasında fark 
yoktu (p = 0,338). Hastaların yaşı, ortalama infertilite süresi, serum FSH, LH, 
testosteron, östradiol düzeyleri ve testis hacimleri açısından iki grup arasında 
anlamlı farklılık saptanmadı (p> 0,05). FR, IR, PR, LBR açısından iki grup ara-
sında istatistiksel olarak anlamlı fark saptanmadı (p> 0,05). Tartışma: idiyo-
patik NOA hastalarda ampirik hCG tedavisi ile SRR iyileşme sağlanamamış-
tır. hCG tedavisinin ICSI başarısı üzerinde herhangi bir etkisi bulunamamıştır.
Anahtar Kelimeler
Azospermi; Hormon Tedavisi; Sperm Eldesi; Gebelik Oranı
Abstract
Aim: To investigate our experience on empirical hCG treatment of patients 
with idiopathic non-obstructive azoospermia (NOA). Material and Method: 
hCG group consisted of 34 patients who were empirically treated with hCG 
despite normal serum FSH and LH levels and normal testicular volumes. hCG 
was administered as 2500 IU twice weekly subcutaneous injections for 10 
to 14 weeks prior to testicular sperm extraction (TESE). Control group con-
sisted of 49 age and spouse age matched patients who underwent TESE in 
the same time period. Sperm retrieval rate (SRR), and follicle stimulating 
hormone (FSH), lutenizing hormone (LH) and testosterone levels, volume of 
testicles, fertilization rate (FR), implantation rate (IR), pregnancy rate (PR), 
live birth rate (LBR) and cancel rate (CR) and surgical technique were com-
pared between the two groups. Results: Conventional technique was used 
in 14 of the 17 patients (82.3%) with successful sperm retrieval in the hCG 
group, and 18 of the 28 patients (64.3%) in the control group (p=0.170). 
There were no differences between groups in terms of SRR (p=0.338). There 
were no significant differences in patient age, mean infertility period, mean 
values of FSH, LH, testosterone, estradiol levels, and testis volume between 
the two groups (p>0.05). There were no statistically significant differences 
for FR, IR, PR, LBR between the two groups (p>0.05). Discussion: Empirical 
hCG treatment in patients with idiopathic NOA did not result in improved 
SRR. hCG treatment did not have any effect on the success of ICSI.
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Introduction
Azoospermia defined as the absence of spermatozoa in the 
ejaculate after assessment of centrifuged semen on at least 
two occasions, is observed in 1% of the general population and 
in 10–15% of infertile men [1, 2]. Non-obstructive azoospermia 
(NOA) refers to absence of spermatozoa in semen analysis due 
to minimal or no production of fully developed spermatozoa in 
the testicles. NOA results from a testicular failure. This problem 
affects 10% of infertile men and is diagnosed in 60% of azo-
ospermic men [2, 3]. Hypospermatogenesis, maturation arrest 
and Sertoli cell-only syndrome (SCOS), with or without focal 
spermatogenesis are the commonest histological patterns of 
patients with NOA. 
The positive clinical outcome of gonadotrophin treatment for 
infertile men whose azoospermia is caused by hypogonado-
tropic hypogonadism has been well documented. However, no 
established hormonal therapy is available for treatment of men 
with idiopathic NOA and normal plasma gonadotrophin levels.
A recent survey among American Urological Association mem-
bers showed that two thirds of the respondents used empiri-
cal medical therapy for idiopathic male infertility and the most 
common medications used were clomiphene citrate, human 
chorionic gonadotropin and anastrozole [4] Overall 60.5% of re-
spondents would treat with empirical therapy for 3 to 6 months 
and 70% of the fellowship trained urologist counselled patients 
that empirical medical therapy has unknown effects on preg-
nancy and sperm count. The authors concluded that there is 
need for additional studies to establish recommendations on 
the empirical use of medical therapy in the setting of male in-
fertility.
We aimed to investigate our own experience on empirical hCG 
treatment of patients with idiopathic NOA and normal plasma 
gonadotrophin and testosterone levels. We retrospectively ex-
amined the effects of empirical hCG treatment on sperm re-
trieval rate by TESE procedure and the success of intracyto-
plasmic sperm injection (ICSI) performed with the extracted 
sperm. 
 
Material and Method
In a retrospective Case – Control study we reviewed the files 
of 429 consecutive patients with NOA who underwent TESE 
between March 2004 and November 2010. We identified 34 
patients who were empirically treated with hCG despite nor-
mal serum FSH (1-12 mIU/ml) and LH(2-10 mIU/ml) levels and 
normal testicular volumes (≥ 15 cc) (hCG group). The hCG was 
administered as 2500 IU twice weekly subcutaneous injections 
for 10 to 14 weeks prior to TESE. TESE was performed by the 
conventional method initially, and carried on as microdissec-
tion TESE in the same session if the conventional technique 
failed to retrieve sperms. Control group consisted of 49 age 
and spouse age matched patients who underwent TESE in the 
same time period, had normal serum FSH and LH levels and 
normal testicular volumes, and did not receive hormone treat-
ment. None of the couples in the treatment or control groups 
had any female factors involved.
The presence of azoospermia was confirmed by at least two se-
men analyses. Serum FSH, LH, testosterone (1.66-8.77 ng/ml) 
and estrodiol (11-44 pg/ml) levels were measured in all patients 
in the morning after 8 hours of overnight fasting. Testicular 
volume was measured in all patients by using an orchidometer. 
Informed consent was obtained from all patients before the op-
eration. 
The study was conducted according to the ethical standards 
of the Declaration of Helsinki. Since this was a retrospective 
design no ethical committee approval was seeked. 
None of the patients in the study had karyotype abnormalities 
or Y chromosome microdeletion.
The relation between SRR and FSH level, LH level, testoster-
one level and the volume of testicles were compared between 
groups. Additionally, FR, IR, PR, LBR and CR were determined. 
Relation between SRR and surgical technique was also ana-
lyzed. 
In patients who underwent conventional TESE, microdissection 
TESE was also performed if the conventional technique failed 
to retrive sperms [5]. Conventional and microdissection TESE 
procedures were performed under spinal anaesthesia. For con-
ventional TESE, the tunica albuginea was incised for approxi-
mately 5mm at the upper pole near the head of the epididy-
mis. If no sperms were seen in the initial sample, subsequent 
samples were taken from the middle part and the lower pole 
of the testis opposite the rete testis. When there was not a 
sufficient number of spermatozoa in the tubules obtained from 
these fields, the procedure was continued (maximum 7 biop-
sies) until sufficient spermatozoa were collected. The procedure 
was terminated when sufficient sperm were retrieved. When no 
sperm could be detected in 3 poles through the conventional 
technique, microdissection TESE was performed by enlarging 
the middle incision vertically (Combined technique). For micro-
dissection TESE, the subtunical vessels were identified under 
the surgical microscope and avoided. Direct examination of the 
testicular parenchyma was performed at ×20 to ×40 magnifica-
tion with an operating microscope. Small samples were excised 
from large, opaque seminiferous tubules. The procedure was 
terminated when a sufficient volume of spermatozoa had been 
retrieved for intracytoplasmic sperm injection. When there was 
no sperm in one testis, these procedures were performed on the 
contralateral testis. At the same session, a surgically-obtained 
small tissue specimen was placed in Bouin’s solution and sent 
to the histopathology laboratory [5].
Ovarian stimulation and ICSI procedure [6]: 
We used long luteal GnRH agonist protocol, ovarian down-
regulation was initiated with daily leuprolide acetate 1 mg 
(Lucrin, Abbott, France), beginning on day 21 of the preced-
ing menstruation (last 3 tablets of OCP). After ovarian sup-
pression was achieved, the dose was reduced to 0.5 mg until 
the day of hCG. If there were no cysts ≥2 cm and the E2 was 
<50 pg/mL, gonadotropin stimulation with 150-300 IU of rFSH 
was performed, with E2 monitoring commencing on the morn-
ing of stimulation day 5. Ultrasound and blood E2 monitoring 
continued until hCG administration criteria were met with at 
least three follicles having a maximum diameter of >17 mm. 
Transvaginal ultrasound-guided oocyte retrieval was performed 
35-36 hours after 10,000 IU hCG injection. An oocyte pick-up 
was performed with a 17-gauge single lumen needle for oocyte 
retrieval under sedation with propofol (propofol 1% Fresenius 
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KabiR, Germany). The oocyte-corona complexes (OOC) were de-
nuded, and ICSI was performed after 2 hours of incubation and 
embryos were transferred on day 3. Our clinical policy is to use 
ICSI routinely in all patients. All patients had luteal support with 
90 mg of progesterone intravaginally daily after embryo trans-
fer until gestation reaches to 8 weeks. 
Statistical analysis:
Statistical analysis was performed using the statistical pack-
age SPSS v 17.0 (SPSS Inc. Released 2008. SPSS Statistics 
for Windows, Version 17.0. Chicago, USA: SPSS Inc.). For each 
continuous variable, normality was checked by Kolmogorov 
Smirnov and Shapiro-Wilk tests and by histograms. Comparison 
between groups was made with Mann Whitney-U test for data 
not normally distributed and with student’s t test for data nor-
mally distributed. The categorical variables between the groups 
were analyzed by the Chi-square test. Values of p < 0.05 were 
considered statistically. 
 
Results
Spermatozoa were retrieved in 195 of 429 (45.5%) patients 
with NOA in whom TESE was performed. The hCG group con-
sisted of 34 patients who received hCG treatment prior TESE, 
and the control group consisted of 49 patients who did not re-
ceive hCG treatment. There were no significant differences in 
patient age, mean infertility period, mean values of FSH, LH, 
testosterone, estradiol levels, and testis volume between the 
two groups (Table 1). 
In the hCG group, TESE was performed by conventional tech-
nique in 14 (41.2%), and combined technique in 20 (58.8%) pa-
tients. In the control group, TESE was performed by convention-
al technique in 18 (36.7%), combined technique in 31 (63.3%) 
patients (p=0.428). Sperm retrieval was achieved in 17 patients 
(50%) in the hCG group and 28 patients (57.1%) in the control 
group. There were no differences between groups in terms of 
SRR (p=0.338). Conventional technique was used in 14 of the 
17 patients (82.3%) with successful sperm retrieval in the hCG 
group, and 18 of the 28 patients (64.3%) in the control group 
(p=0.170). 
None of the patients showed any acute or chronic complications 
after TESE. No side effects of the treatment were observed. 
We were not able to perform postoperative serum testosterone 
level measurements in most of the patients due to low patient 
compliance, therefore postoperative testicular failure could not 
be evaluated. 
When the spouses were concerned, there were no differences 
between the groups for age, basal FSH level, antral follicle 
count, of the spouses and the number of transfered embryos 
(Table 2). There were no statistically significant differences for 
FR, IR, PR, LBR between the two groups (Table 3). In the hCG 
group sperms were retrieved in 17 patients. At the time of this 
report sperm was still cryopreserved in one patient. Embryo 
transfer was cancelled in one patient because of fertilization 
failure. In the remaining 15 patients 26 cycles of ICSI were per-
formed which yielded 15 pregnancies and 10 live births (Figure 
1a). In the control group sperms were retrieved in 28 patients. 
At the time of this report sperm was still cryopreserved in one 
patient. Embryo transfer was cancelled in three patients, two 
due to fertilization failure, and one because no mature oocytes 
could be found. In the remaining 27 patients 31 cycles of ICSI 
were performed which yielded 20 pregnancies and 17 live births 
(Figure 1b).
In the hCG group hypospermatogenesis, maturation arrest, and 
Sertoli cell only were found in 14.7%, 79.4% and 5.9% of the 
patients, respectively. In the control group hypospermatogene-
sis, maturation arrest, and Sertoli cell only were found in 10.2%, 
71.4%, and 18.4% of the patients, respectively. There was no 
difference in the histopathological findings between the hCG 
and the control groups (p=0.238). Spermatozoa were success-
fully retrieved in all patients with hypospermatogenesis. In pa-
tients with maturation arrest spermatozoa were retrieved in 12 
(44.4%) and 19 patients (54.3%) in the hCG and control groups, 
respectively. In Sertoli cell only patients spermatozoa could be 
retrieved in none of the patients in the hCG group, and in 4 
patients (44.4%) in the control group. 
 
Table 1. Comparison of clinical and laboratory data for patients
hCG Group Control Group P
Age, (years) 34±5.7 33.1±3.8 0.316*
Infertility time, (years) 7±5 6.6±4.2 0.706**
Age of the spouses, (years) 28±4.2 28±3.9 0.815*
FSH, mIU/ml 7±3.9 8±3.6 0.086**
LH, mIU/ml 4.2±1.5 4.7±1.9 0.298**
Testosteron, ng/ml 5±2 5.1±1.8 0.113**
Estradiol, pg/ml 22±9.1 23.6±9.4 0.381**
Testis volume, ml 20±4 20±3 0.546*
FSH: follicle-stimulating hormone, LH: luteinizing hormone.
Values are presented as mean±SD.
*Student’s t test, **Mann Whitney-U test
Table 2. Clinical characteristics of the spouses and the number of transferred 
embryos in the hCG and the control groups
hCG Group Control Group p
Female Age 29.8±4.9 28.2±5.3 0.08*
Basal FSH 6.2±1.8 5.6±1.5 0.65*
AFC 6.1±2.7 6.7±2.5 0.14**
Number s of transferred embryos 2.4±1.2 2.9±1 0.55**
AFC: Antral follicle count; FSH: follicle stimulating hormone
Values are presented as mean±SD.
*Student’s t test, **Mann Whitney-U test
Table 3. Comparison of fertilization, implantation, pregnancy and birth rates in 
the hCG and the control groups
hCG Group Control Group p
Fertilization Rate 60.7±25.3 54.4±26.2 0.392*
Implantation Rate 60.1±26.3 53.1±26.1 0.459*
Pregnacy Rate (per started cycle) 57.7(15/26) 64.5(20/31) 0.339**
Live Birth Rate (per started cycle) 38.5(10/26) 54.8(17/31) 0.167**
Live Birth Rate (per patient) 62.5(10/16) 63(17/27) 0.613**
Cancel Rate 6,3 11.1 0.567**
Numbers are given as percentages (%).
*Mann Whitney-U test, **Chi-square test
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Discussion
The role of hormonal treatment is well established for male 
infertility caused by hypogonadotropic hypogonadism [7-9]. On 
the other hand the effect of hormonal treatment in patients 
with idiopathic NOA is not clear.
The actions of FSH and LH on germ cells are indirect and me-
diated by paracrine signals from Sertoli and Leydig cells, and 
close cell–cell interactions are required to maintain normal 
spermatogenesis [10]. hCG has effects similar to LH on the tes-
ticles. It was generally believed that gonadotrophin treatment 
would be ineffective in the presence of high plasma levels of en-
dogenous gonadotrophin. Previous attempts to improve sper-
matogenesis in men with NOA by treatment with either recom-
binant human (rh)-FSH alone or in combination with hCG have 
been partly successful [9, 11]. Shiraishi and coworkers studied 
the effect of human chorionic gonadotrophin treatment prior to 
second microdissection testicular sperm extraction after failed 
previous micro-TESE in men with NOA. Fourty-eight men with 
NOA who had negative sperm retrieval results by the micro-
TESE procedure were studied. Twenty patients did not receive 
any medical treatment and 28 patients received 5000 IU sub-
cutaneous injections of hCG three times a week prior to the 
second micro-TESE. In the treatment group all of the patients 
received hCG for 3 months. At the end of this period 15 patients 
with low serum FSH levels received rec FSH in addition to hCG 
for 2 months. Thirteen patients with normal FSH levels received 
hCG only for additional 1 to 2 months. No spermatozoa were re-
ceived from the 20 patients in the no medical treatment group. 
In the hCG only group, spermatozoa were retrieved in 2 of 13 
patients (15.4%). In the recFSH + hCG group spermatozoa were 
retrieved in 4 of 15 patients (26.7%). The authors concluded 
that hCG-based hormonal therapy prior to second micro-TESE 
attempt is effective in some men with NOA and normal FSH 
levels, and that increased intratesticular testosterone following 
hCG treatment promotes spermatogenesis [12].
Efesoy and coworkers treated 16 patients with oligoasthen-
spermia and 11 patients with maturation arrest with 100-150 
IU rhFSH 2-3 times /week. They detected no difference in to-
tal motile sperm counts before and after treatment in patients 
with oligoasthenspermia. On the other hand in the maturation 
arrest group 2 patients had (18.1%) spermatozoa in the ejacu-
late, and 2 patients had (18.1%) spermatozoa on TESE after 
treatment. They concluded that rhFSH may have some positive 
effects in patients with maturation arrest by providing sperm in 
the ejaculate or TESE [9].
Our study group consisted of patients with idiopathic NOA 
who had not previous TESE procedure. The treatment did not 
cause any differences on SRR and surgical method. However, 
even though not statistically significant, sperm retrieval was 
achieved by conventional technique in more patients in the 
treatment group (82.3% versus 64.3%). This result may be re-
garded as a possible positive effect of empirical hCG treatment. 
TESE procedure can be performed faster when compared to 
microdissection technique and this may be regarded as clini-
cally significant. None of the patients in our study showed any 
acute or chronic complications after TESE. In the literature it 
has been reported that although fewer complications occur af-
ter microTESE clinical complication rate between microdissec-
tion and conventional technique are similar [13]. 
Our doses are lower than given by Shiraishi and coworkers who 
used 5000 IU subcutaneous injections of hCG three times a 
week for 4 to 5 months. There are no accepted guidelines on 
the dosage of hCG for the empirical treatment of NOA. All pa-
tients in our group had normal serum FSH levels, therefore we 
did not administer FSH. Considering results from the study of 
Efesoy and coworkers, administering FSH along with hCG might 
be useful in an additional percentage of patients. 
Similar results after ICSI between the hCG and control groups 
show that the hCG treatment does not have any negative effect 
on the fertilization capacity of the retrieved sperms. Fertiliza-
tion and pregnancy live birth rates were studied in patients with 
NOA. In NOA, FR, CPR, LBR has been reported as 38.6-64.4% 
[14, 15], 21-42.9% [14, 16], and 20-42.9% [14, 16], respectively. 
Our fertilization and pregnancy rates in patients with NOA are 
similar with the previous reports of patients with NOA. This 
implies that empirical hCG treatment does not have any effect 
on fertilization and pregnancy rates. 
Aydin and co-workers reported [17] that sperm retrieval rates 
are higher in hypospermatogenesis than MA and SCOS and 
fertilisation and pregnancy rates are similar once successful 
sperm retrieval is achieved. In the present study spermatozoa 
were successfully retrieved in all patients with hypospermato-
genesis. In patients with maturation arrest spermatozoa were 
retrieved in 12 (44.4%) and 19 patients (54.3%) in the hCG and 
control groups, respectively. In Sertoli cell only patients sper-
matozoa could be retrieved in none of the patients in the hCG 
group, and in 4 patients (44.4%) in the control group.
Testicular sperm extraction (TESE) along with ICSI is a first-line 
treatment modality for patients with NOA 15 Sperm retrieval 
rates (SRR) in TESE operations ranges from 41.6% to 89.6% 
[18, 19]. Microdissection TESE is currently the best method for 
the definitive identification of spermatozoa, resulting in a high 
spermatozoa retrieval rate and minimal postoperative compli-
cations for patients with NOA [5, 20]. However microdissection 
technique is lengthier and more costly than the conventional 
technique. In the present study successful sperm retrieval was 
achieved by the conventional technique in 14 of the 17 patients 
(82.3%) in the hCG group, and 18 of the 28 patients (64.3%) in 
the control group. The dose and time of hCG given to patients 
with NOA did not prove to be useful in this study. One of the 
possible causes for this is may be the dose and time of treat-
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ment. Reifsnyder and coworkers evaluated the role of medical 
therapy in men with NOA before microdissection TESE [21]. 
They treated men with preoperative testosterone levels less 
than 300 ng/dl with aromatase inhibitors, clomiphene citrate 
or hCG. This study showed that such treatment was able to ele-
vate testosterone levels however neither baseline testosterone 
level nor response to hormonal treatment affected sperm re-
trieval rate. In another study from the same center, Ramasamy 
and coworkers reported that men with Klinefelter’s syndrome 
who respond to medical therapy with a resultant testosterone 
higher than 250 ng/dl, may have a better chance of sperm re-
trieval [22]. The limitations of this study include retrospective 
design and low number of patients. Prospective trials in which 
different doses of hCG administered for various time periods, 
combinations with other agents, and comparison the results of 
hormonal manipulations in men with or without established hy-
pogonadism would be the next steps. 
Empirical hCG administered as 2500 IU twice weekly subcuta-
neous injections for 10 to 14 weeks prior to TESE in patients 
with idiopathic NOA did not result in improved SRR. hCG treat-
ment did not have any effect on the success of micro-injection. 
Prospective studies may prove useful to define any role of em-
pirical hormonal treatment in patients with idiopathic NOA. 
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